 Among patients who are CA19-9 producers, but have insufficient material for molecular profiling to be performed, patients will receive induction FOLFIRINOX, as standard therapy. Patients who demonstrate a response or stable disease at the first treatment assessment will be maintained on the same chemotherapy for an additional two months. Patients who demonstrate local disease progression deemed amenable to surgical resection will be switched to chemoradiation, undergo restaging assessment and be offered surgery in the absence of further disease progression. Patients who demonstrate metastatic disease progression will removed from the trial. Among the patients who complete four months of chemotherapy, restaging assessment will be performed, using imaging CT scan, biomarker serum CA19-9 and performance status. In the absence of local disease progression deemed inoperable, or metastatic disease progression, patients will be treated with chemoradiation 50.4Gy in 28 fractions. A third restaging assessment will be performed, and in the absence of inoperable local progression or metastatic disease progression, patients will be offered surgical resection. Patients who did not receive four months of systemic therapy in the neoadjuvant setting will be offered four months of adjuvant therapy at the discretion of their treating physicians. 